Epidural haloperidol enhances epidural morphine analgesia: Three case reports

George Colclough, MD; John T. McLarney, MD; Paul A. Sloan, MD; K. Todd McCoun, MD; Gregory L. Rose, MD; J. S. Grider, MD; P. Steyn, MD

doi:10.5055/jom.2008.0021

Authors

George Colclough, MD
John T. McLarney, MD
Paul A. Sloan, MD
K. Todd McCoun, MD
Gregory L. Rose, MD
J. S. Grider, MD
P. Steyn, MD

DOI:

https://doi.org/10.5055/jom.2008.0021

Keywords:

epidural haloperidol, epidural morphine, analgesia, epidural analgesics

Abstract

Epidural opioids provide significant postoperative analgesia; however, their use is often limited by side effects such as nausea and pruritus, or they require the addition of epidural local anesthetics with possible side effects of motor block and hypotension. Adjuncts to epidural opioid analgesia would benefit pain management. There is evidence that epidural butyrophenones may enhance opioid analgesics and reduce side effects. The authors present the first reported use of epidural haloperidol to enhance epidural morphine analgesia in three individuals. Pharmacodynamic interactions of haloperidol, which may explain its analgesic efficacy, are summarized.

Author Biographies

George Colclough, MD

Department of Anesthesiology, University of Kentucky Hospital, Lexington, Kentucky.

John T. McLarney, MD

Department of Anesthesiology, University of Kentucky Hospital, Lexington, Kentucky.

Paul A. Sloan, MD

Department of Anesthesiology, University of Kentucky, Lexington, Kentucky.

K. Todd McCoun, MD

Department of Anesthesiology, University of Kentucky Hospital, Lexington, Kentucky.

Gregory L. Rose, MD

Department of Anesthesiology, University of Kentucky Hospital, Lexington, Kentucky.

J. S. Grider, MD

Department of Anesthesiology, University of Kentucky, Lexington, Kentucky.

P. Steyn, MD

Department of Anesthesiology, University of Kentucky, Lexington, Kentucky.

References

Sloan PA: Oxymorphone in the management of pain. Ther Clinical Risk Manage. 2008; 4: 1-11.

Sloan PA: Neuraxial pain relief for intractable cancer pain. Curr Pain Headache Rep. 2007; 11: 283-289.

Ackerman WE, Juneja MM, Kaczorowski DM, et al.: A comparison of the incidence of pruritis following epidural opioid administration in the parturient. Can J Anaesth. 1989; 36: 388-391.

Iijima T, Ishiyama T, Kashimoto S, et al.: A comparison of three different concentrations of ropivacaine with fentanyl for patientcontrolled epidural analgesia. Anesth Analg. 2007; 105: 507-511.

Janssen PA: The evolution of the butyrophenones, haloperidol and trifluperidol, from meperidine-like 4-pheylpiperidines. Int Rev Neurobiol. 1965; 8: 221-263.

Greene MJ: Some aspects of the pharmacology of droperidol. Br J Anaesth. 1972; 44: 1272-1276.

Maltbie AA, Cavenar JO Jr, Sullivan JL, et al.: Analgesia and haloperidol: a hypothesis. J Clin Psychiatry. 1979; 40: 323-326.

Kotake Y, Matsumoto M, Ai K, et al.: Additional droperidol, not butorphanol, augments epidural fentanyl analgesia following anorectal surgery. J Clin Anesth. 2000; 12: 9-13.

Buttner M, Walder B, von Elm E, et al.: Is low-dose haloperidol a useful antiemetic? A meta-analysis of published and unpublished randomized trials. Anesth Analg. 2004; 101: 1454-1463.

Kest B, Mogil JS, Sternberg WF, et al.: Antinociception following 1,3-di-0-tolylguanidine, a selective sigma receptor ligand. Pharma Biochem Behav. 1995; 50: 587-592.

Martin WR, Eades CG, Thompson JA, et al.: The effects of morphine- and Nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976; 197: 517-532.

Hanner M, Moebius FF, Flandorfer A, et al.: Purification, molecular cloning, and expression of the mammalian sigma1- binding site. Proc Natl Acad Sci USA. 1996; 93: 8072-8077.

Terashvili M, Wu H, Moore RM, et al.: (−)-Morphine and (−)-morphine stereoselectivity attenuate the (−)-morphineproduced tail-flick inhibition via the naloxone-sensitive sigma receptor in the ventral periaqueductal gray of the rat. Eur J Pharmacol. 2007; 571: 1-7.

Su TP, Hayashi T: Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem. 2003; 10: 2073-2080.

Chien CC, Pasternak GW: Functional antagonism of morphine analgesia by (−)-pentazocine: evidence for an antiopioid sigma-1 system. Eur J Pharmacol. 1993; 250: R7-R8.

Mei J, Pasternak GW: Modulation of brainstem opiate analgesia in the rat by sigma-1 receptors: a microinjection study. J Pharmacol Exp Ther. 2007; 322: 1278-1285.

Alonso G, Phan V, Guillemain I, et al.: Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience. 2000; 97: 155-170.

Cendan CM, Pujalte JM, Portillo-Salido E, et al.: Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology 2005; 182: 485-493.

Sloan PA, Hamann SR: Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manage. 2006; 2: 295-304.

Whittemore ER, Ilyin VI, Woodward RM: Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. J Pharmacol Exp Ther. 1997; 282: 326-338.

Debonnel G, de Montigny C: Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci. 1996; 58: 721-734.

Ilyin VI, Whittemore ER, Guastella J, et al.: Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol. 1996; 50: 1541-1550.

Olschewski A, Brau ME, Hempelmann G, et al.: Differential block of fast and slow inactivating tetrodotoxin-sensitive sodium channels by droperidol in spinal dorsal horn neurons. Anesthesiology. 2000; 92: 1667-1676.

Ito K, Nishimura Y, Uji Y, Yamamoto T: Haloperidol effects on Na current in acutely isolated rat retinal ganglion cells. Jpn J Ophthalmol. 1997; 41: 221-225.

Fishbain DA, Cutler RB, Lewis J, et al.: Do the secondgeneration atypical neuroleptics have analgesic properties? A structured evidence-based review. Pain Med. 2004; 5: 359-365.

Thorn SE, Wattwil M, Kallander A: Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake. Acta Anaesthesiol Scand. 1994; 38: 57-62.

Nakata K, Mammoto T, Kita T, et al.: Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia. J Clin Anesth. 2002; 14: 1121-1125.

Lee IH, Lee IO: The antipruritic and antiemetic effects of epidural droperidol: a study of three methods of administration. Anesth Analg. 2007; 105: 251-255.

Eisenach JC, Hood DD, Curry R: Phase I human safety assessment of intrathecal neostigmine containing methyl- and propylparabens. Anesth Analg. 1997; 85: 842-846.

Grip G, Svensson BA, Gordh T, et al.: Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat. Acta Anaesthesiol Scand. 1992; 36: 145-152.